Oncology
Browse Menu
At MAC Clinical Research, we are committed to ensuring that people living with and beyond cancer have access to groundbreaking clinical trials which aim to deliver improvements in their diagnosis, treatment, clinical outcomes and quality of life.
We are dedicated to ensuring that the latest oncology research innovations are delivered rapidly to the highest standard, on time and to target, across a developing network of investigator sites.
Our oncology CRO capabilities encompass all stages of clinical development, across a variety of anti-cancer therapy induced toxicities, solid tumours, and haematological malignancies. We offer flexible full-service solutions including quality assurance; project management; IMP manufacture and distribution; site feasibility and clinical operations; participant recruitment, engagement, and retention; regulatory affairs and pharmacovigilance; biometrics including data management, SAS programming, medical writing and statistical analysis; and vendor management.
As a CRO partner, MAC can navigate the complexities that oncology clinical trials typically face. Whether that be in protocol development, the intensive logistical management of biomarker-driven precision oncology or operational challenges arising from capacity issues within investigator sites; our clinical research professionals are on hand to help.
We can leverage our scientific and operational expertise to provide the following to meet your oncology research needs:
- Our teams can support with the delivery of studies with complex and adaptive trial designs, and the identification of clinical and surrogate endpoints to meet regulatory requirements.
- We can deliver optimised patient selection with the logistical management of biomarker driven precision oncology trials.
- Working closely with our oncology imaging partner, we can provide blinded independent central review (BICR) services, for assurance of lack of tumour assessment bias, utilising RECIST (version 1.1) as response criteria where applicable.
- Through formed partnerships, we can select investigator sites based on direct insights into patient population access to ensure recruitment success.
- We can support our developing network of partner investigator sites facing capacity challenges, to optimise research delivery and expedite study start up and recruitment timelines with the provision of our supportive functional services.
- We can utilise our GMP manufacturing capabilities at our MHRA (MIA) IMP licensed facility which includes the preparation of aseptically prepared products such as manipulation of previously formulated products, cytotoxic and monoclonal antibodies.